

EXPRESS MAIL CERTIFICATE

Date 4/13/01 Label No. 885359913215

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail-Post Office to Addressee" service.

Name (Print) D.B. Peck

Signature DBP

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

Docket No.:3380/1I127-US4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Application of: Papsidero et al.

Serial No: TBA

Examiner: TBA

Filed: Concurrently Herewith

Group Art Unit: TBA

For: DETECTION AND TREATMENT OF BREAST DISEASE

---

**PRELIMINARY REMARKS**

Hon. Commissioner of Patents  
Washington, DC 20231

Sir:

Prior to examination of the application submitted herewith, consideration of the following remarks is requested. The present application is a divisional application of pending U.S. Patent Application Serial No.: 09/146,580 filed on September 3, 1998. The present application contains amendments to the specification.

- (1) The application has been amended to reflect the continuing data.
- (2) The sequence identification numbers have been revised to follow the sequence listing submitted herewith.

(3) The description of Figure 1 (page 5, lines 17-26) has been amended to incorporate new SEQ ID NOs: 20-34 present in the figure. Support for these sequences is in original Figure 1.


(4) SEQ ID NO: 7 (see page 20, lines 20-27) has been amended to correctly identify the coding sequence of the protein depicted in SEQ ID NO:1. The encoded protein (SEQ ID NO:1) contains a methionine residue in position 1. In order for SEQ ID NO:7 to encode a methionine residue at position 1, the first codon should be ATG, not TGC (which is the codon for cysteine). Clearly, a typographical error resulted in omission of the 5'-most "A" base. Support for this nucleic acid sequence is found on page 18, line 8 to page 20, line 4 of the parent application (specifically, see residues 46-430) and the deduced amino acid sequence (page 6, lines 21-23).

(5) Reference to Table 1, ID#189 on page 44, lines 2-4 in the original specification has been amended to refer to Table 3, ID#189 (see page 45, lines 1-5). ID#189 is described in Table 3, not Table 1, of the original specification.

No new matter has been added by these amendments.

Respectfully submitted,

Dated: April 13, 2001

  
Neepa Y. Choksi  
Registration No. 47,488  
Agent for Applicant(s)